Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
FARMINGTON, Conn., Dec. 22, 2016 -- Immuron Limited: The latest travel forecast released this week by AAA, projects that 103 million Americans will travel during the December 23, 2016 – January 2, 2017 Holiday Season. Many of those travelers will become ill, or experience intestinal discomfort, from the food they eat along the way.
|
|||
While food-borne, E. coli-based illnesses are certainly of concern during international travel, last year’s largest E. coli outbreak was actually in the United States - at several Chipotle’s restaurants. So it’s important to be prepared to minimize the risk of food/water-borne illness wherever you are traveling, both domestically and abroad.
Travelan is a supplement that was developed by Australian bio-pharmaceutical company, Immuron Ltd., to help protect your intestinal track against the 13 most commonly occurring strains of E. coli*. Popular in its native Australia for the past 10 years, and in Canada for the past three years, Travelan is now available in the United States on CVS.com and in select CVS/pharmacy stores, on Amazon.com, at Passport Health clinics and other travel medical providers.
About Travelan:
- Travelan is a non-prescription supplement uniquely formulated to be high in antibodies that can help support and maintain gastrointestinal and digestive function and health.
- Travelan’s active ingredient is Hyperimmune Bovine Colostrum Powder, which has been specifically engineered to be a rich source of antibodies that bind to Enterotoxigenic E. coli in the gastrointestinal tract, preventing them from attaching to the intestinal wall and thereby neutralizing their ability to cause diarrhea and its associated symptoms.
- Hyperimmune Colostrum is developed under Immuron’s Proprietary Technology to create high titers of antibodies to a range of E. coli bacteria that is present in normal colostrum in only very small amounts.
About Immuron Limited:
Immuron Limited™ is a publicly listed Australian bio-pharmaceutical company (ASX:IMC) focused on oral immunotherapy using polyclonal antibody products. Immuron is a uniquely positioned company developing therapeutic products in NASH (fatty-liver disease), ASH (alcoholic fatty-liver disease) and other diseases mediated through gut dysbiosis.
Visit www.Immuron.com to learn more about the company or www.TravelanUSA.com to learn more about Travelan.
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Media Contact: Kathy Kaschuluk [email protected]
